How much exercise heart failure inpatients can perform? by Delgado, Bruno et al.
European Journal of Heart Failure (2020) 22 (Suppl. S1) 2–415
doi:10.1002/ejhf.1963
Basic Science – Vascular Diseases: Biomarkers
22
Development of reactive pulmonary hypertension induced by left heart failure
can be predicted by the assessment of the level of new biomarkers - results
on experimental rat model
M Milan Chovanec1; F Malek2; Z Jiraskova-Zakostelska3; J Durisova4; B Kaftanova4;
T Andreasova2; J Herget4; 1Charles University of Prague and Na Homolce Hospital,
Prague, Czechia; 2Na Homolce Hospital, Cardiology department, Prague, Czechia;
3Academy of Sciences of the Czech Republic, Laboratory of Cellular nad Molecular
Immunology, Institute of Microbiology , Prague, Czechia; 4Charles University Prague,
2nd Faculty of Medicine, Department of Physiology, Prague, Czechia;
Funding Acknowledgements: Grant Agency of the Czech Republic (GACR)
17-11223S and Institutional Research Grant MH-CZ DRO NNH 00023884 IG160502
and IG190501
Introduction: The most common cause of pulmonary hypertension (PH) in patients
is due to left heart failure (HF). Diagnosis of early stages of HF or PH have not
been clearly obvious, recently. Elevated filling pressures in the heart and pulmonary
vascular remodelling is associated with expression changes of the various plasma
levels of biomarkers.
Purpose: To assess the plasma levels of HF biomarkers on a new rodent model of
HF induced by the left ventricle pressure-overload which leads to the development
of reactive PH consist of pulmonary vascular remodelling.
Methods: The left heart failure was induced by pressure overload in adult male
Wistar rats by inserting a polyethylene tubing into aorta trough the right carotid
artery. Three weeks later experimental animals were studied (the group E, n=6)
and compared to the controls (n=6). Serial venous blood samples were taken
from both experimental groups to determine levels of biomarkers involved in
pathophysiology cardiac and vascular remodelling: Troponin I, N-proBNP, Copeptin,
Apelin, Endostatin, Asymmetric dimethylarginine (ADMA), Growth/differentiation
factor 15 (GDF-15), Ceruloplasmin and Cystatin-C. The biomarker levels were
assessed by ELISA method.
Results: The left ventricle end-diastolic pressure was elevated in the group E
(1.34±0.07 mmHg vs. 0.41±0.13 mmHg in the controls; p<0.0001). Mean pulmonary
arterial blood pressure measured by catheterization was increased 22.9±0.7 mmHg
compared to the controls 16.9±1.0 mmHg; p<0.05. Weight of the right ventricle
relative to body weight was 5.5±0.3.10-4 compared to the controls 4.6±0.2.10-4;
p<0.05. In lung histology, 74% of small pulmonary vessels had muscularized media
(24% in controls; p<0.01).
Elevated blood plasma levels of biomarkers in the group E compared to the controls
were found in: NT-proBNP (671.8±61.2 pg.mL-1 vs. 450.3±47.5 pg.mL-1; p<0.05;
respectively) and Copeptin (251.9±41 pg.mL-1 vs. 141.3±10.1 pg.mL-1; p<0.05;
respectively). Significantly decreased blood plasma levels of biomarkers in the
group E compared to the controls were found in the values of Apelin (4.0±0.09
ng.mL-1 vs. 4.3±0.05 ng.mL-1; p<0.05; respectively) and ADMA (12.1±0.5 mg.mL-1
vs. 15.3±0.8 mg.mL-1; p<0.05; respectively). We found no significant changes in
the blood plasma levels compared to the controls in the values of TnI, GDF-15,
Endostatin, Cystatin-C and Ceruloplasmin.
Conclusion: We develop a brand new rodent model of PH accompanied with pul-
monary vascular remodelling induced by left HF. Presented experimental model
was associated with increased concentration of biomarker of cardiac remodelling:
NT-proBNP and Copeptin and with decreased level of biomarkers that have protec-
tive effect against vascular remodelling: Apelin and ADMA.
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Background: Coronary artery disease (CAD) is the leading cause of death world-
wide, and percutaneous coronary intervention with stenting the most widely
performed procedure to treat CAD. However, current stent monitoring tech-
niques are invasive and/or ionizing. Microwave spectrometry (MWS) may provide
a non-invasive, non-ionizing and cost-effective alternative capable of detecting
stent-related pathologies before they cause fatal heart failure.
MWS response to monitor stent status
Purpose: To develop a new MWS-based technology to monitor coronary stents in
an in vivo swine model.
Methodology: First, using a new MWS device, an in vitro experiment was carried
out to demonstrate: (1) the ability of detecting the presence of a stent and (2) stent
fractures (SF). To that end, an intact stent was distanced 3, 7, 11 and 15 mm from a
MWS near-field probe in open-air conditions. Afterwards, three identical stents were
piecemeal cut to emulate type I, II and III SF at different fractions of the stent’s length
(l): l/5, l/3 or l/2. Additionally, the stent was measured in a phantom substance, to
simulate in vivo conditions: it was distanced from 0 to 40 mm in steps of 5 mm.
Likewise, a pair of MWS far-field antennas measured the stent at 10, 20, 30 and
40 mm.
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rate (74±10 vs 65±8 bpm p<0.001) and mean systolic blood pressure (127±20 vs
120±19 p=0.04) was observed.
13 patients (30%) did not achieved maximum target dose. The main cause was
bradycardia, defined as heart rate <55 bpm (n=7; 16%). During the titration period
no severe adverse effects, emergency visits or hospitalizations were observed.
In a univariate analysis, age, LVEF, NT-proBNP and systolic blood pressure were
not significatively associated with achieving maximum target dose (all p >0.05).
However, a higher heart rate before starting titration (76+/-10 vs 68+/- 9 bpm p=0.02)
was significatively associated with achieving maximum target dose.
Conclusions:
In our study beta-blockers dose titration by trained heart failure nurses was safe and
effective. Most patients achieved maximum target dose, mainly those with a higher
heart rate at baseline. Our results support the crucial role of trained heart failure
nurses in improving management and outcomes in HFrEF patients.
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Introduction: Decompensated Heart Failure (HF) patients have a significant func-
tional dependence, impairment of performance in activities of daily living and low
exercise tolerance. Exercise is a well establish cardiac rehabilitation intervention
which leads to improvement of symptoms. The amount of Exercise is directly related
to its benefits.
Purpose: To evaluate the volume of exercise that HF patients preform during the
hospitalization
Methods: 64 patients performed an aerobic exercise training (AET) program
(ERIC-HF: Early rehabilitation in cardiology – heart failure) with 5 sequential stages:
respiratory training, cyclo ergometer for 5 to 10 min, walking training for 5 to 10 min
and then for 10 to 15 min and walking training for 10 to 15 min followed by 5 min
climbing stairs. The patient progresses on the program according to his synthons.
The volume of exercise is registered in number of turns on the cyclo ergometer,
meters walked, number of steps and total time of exercise. Subjective perception
of exertion using Borg scale, and vital signs are evaluated in every training session
(twice a day for 5 days a week). At discharge patients preform a 6 minute walking
test (6MWT)
Results: Patients performed 932 sessions of AET with an average of 17 sessions
each, for 15 (±9) days of hospitalization. Patients performed progressive periods of
exercise, for more time and with lower levels of perceived exertion, presenting an
average value of 6 (±3) in the admission and 2(±2) at the discharge. 34 patients
reached the final stage of the program (climbing stairs) with an average of 91 steps
in 5 minutes, not continuously. The patients who performed a bigger volume of
Exercise walked more distance in the 6MWT: 291 (±64) meters compared with
patients who didn’t performed stairs: 239 (±27).
Conclusions: AET can be well tolerated by patients admitted due to decompen-
sated HF and patients who are capable to perform a bigger volume of exercise can
improve much more their functional capacity showed by the 6MWT results.
Volume of exercise
Average values
Cycloergometer N∘ of turns 239 (±123)
N∘ of sessions 123
Walking training Meters 425 (±190)
N∘ of sessions 560
Stairs N∘ of steps 108 (±62)
N∘ of sessions 35
Time of exercise 12 minutes
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Background: Chloride is a key electrolyte that regulates the body fluid distribution.
Accordingly, manipulating chloride kinetics by selecting a suitable diuretic could be
an attractive strategy for correcting body fluid dysregulation.
Purpose: This study examined the effects and contributing factors of a
sodium-glucose cotransporter-2 inhibitor (SGLT2i) on the serum chloride con-
centration in type 2 diabetic (T2DM) patients without heart failure.
Methods: Detailed analysis was performed on the data of six T2DM patients
free from heart failure status treated with the SGLT2i empagliflozin (10 mg once
daily). Physical examination, peripheral venous blood tests (hematologic, dia-
betic/metabolic, venous blood gas, and neurohormonal tests), and spot urinary test
(electrolytes) were performed before and 1 month after treatment.
Results: Empagliflozin treatment for 1 month decreased body weight (-3.3±2.2kg),
systolic blood pressure (-11±6.6mmHg), and HbA1c (-0.9±0.5%; p<0.01 for each).
Mild increases in the hemoglobin (+0.23±0.44g/dL) and hematocrit (+0.8±1.2%)
values were detected (5/6, 83%), but the serum creatinine concentration remained
unchanged. The serum chloride concentration increased from 104±2.23 to
106±2.07mEq/L (p<0.006), but the sodium and potassium concentrations did
not change. The spot urinary sodium concentration decreased from 159±43 to
98±35mEq/L (p<0.02) and the spot urinary chloride tended to decrease (from
162±59 to 104±36mEq/L, p<0.08). Both renin and aldosterone tended to be
activated (5/6, 83%). The strong organic acid metabolite concentrations of serum
acetoacetate (from 42±25 to 100±45𝜇mol/L, p<0.02) and total ketone bodies (from
112±64 to 300±177𝜇mol/L, p<0.04) increased, but the actual HCO3- concentration
decreased (from 27±2.5 to 24±1.6mEq/L, p<0.008).
Conclusions: The present study demonstrated that SGLT2i enhances the serum
chloride concentration in T2DM patients and suggests that the effect is mediated by
the possible following mechanisms: 1) enhanced reabsorption of urinary chloride by
aldosterone activation due to blood pressure lowering and blood vessel contraction
effects, 2) reciprocal increase in the serum chloride concentration by reducing
the serum HCO3- concentration via a buffering effect of strong organic acid
metabolites, and 3) reduced NaHCO3 reabsorption and concurrently enhanced
chloride reabsorption in the urinary tubules by inhibiting Na+-H+ exchanger 3 in the
renal proximal tubules. Thus, the diuretic SGLT2i induces excessive extravascular
fluid to drain into the vascular space by the enhanced vascular "tonicity" caused by
the elevated serum chloride concentration.
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Introduction: The renin-angiotensin system (RAS) plays the crucial role in the
development of hypertension. The angiotensin-(1-7) is the metabolic product of
angiotensin II. The apelin is one of the mediators of cardiovascular control. Both
peptides are antagonists to the RAS effects and the important protective cardiovas-
cular factors.
Purpose: The aim of the study was to evaluate the effect of combined treatment with
angiotensin II receptor blocker (ARB) olmesartan or angiotensin-converting enzyme
inhibitor (ACEi) ramipril on the blood levels of angiotensin-(1-7) and apelin in patients
with hypertension and type 2 diabetes (T2D).
Methods: The study involved 76 patients with hypertension grades 2-3 and T2D
(37 men and 39 women) aged 43 to 70. The patients were randomized into
two groups: group O - patients treated with ARB olmesartan (20-40 mg/day)
and calcium channel blocker lercanidipine (10-20 mg/day) (n=38) and group R
- patients who received ACEi ramipril (5-10 mg/day) with lercanidipine (10-20
mg/day) (n=38). All patients treated with lipid-lowering therapy (atorvastatin 20-40
mg/day) and antidiabetic therapy (metformin 1000-2000 mg/day) additionally. The
angiotensin-(1-7) and apelin levels in the blood were determined by ELISA at
baseline and after 12 months of therapy.
Results: Both groups did not differ significantly by angiotensin-(1-7) and apelin
levels at baseline. After 12 months from the start of the treatment in both groups
there was powerful antihypertensive effect, which was not different depending on
the combination of antihypertensive treatment. Targeted blood pressure levels were
reached in 84.2% of patients (n=32) treated with olmesartan and in 81.6% of patients
(n=31) treated with ramipril (p>0.05 - intergroup). In the end of the treatment the
levels of angiotensin-(1-7) were differed significantly only in patients of group O -
there was increasing in its concentration by 20.3% (from 108.39(92.32;121.17) ng/l
to (130.43(124.42;138.37) ng/l, p<0.01). In group R the levels of angiotensin-(1-7)
were 112.09(104.3;115.33) ng/l, which was not significantly different from the basal
levels (p>0.05). There was a significant increase in the levels of apelin in both
groups after 12-month therapy, which did not reach the values of the control
group. Among patients in group O at the end of the treatment, apelin levels were
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